EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Proteomic analyses reveal plasma EFEMP1 and CXCL12 as biomarkers and determinants of neurodegeneration

Michael R Duggan iD, Zhijian Yang, Yuhan Cui, Heather E Dark, Junhao Wen, Guray Erus, Timothy J Hohman, Jingsha Chen, Alexandria Lewis, Abhay Moghekar, Josef Coresh, Susan M Resnick und 2 weitere

Alzheimer's & Dementia · 2024-09 · 20 (9) · 6486-6505

DOI: 10.1002/alz.14142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 11.08.2024. Verfasst von Michael R Duggan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Biomarkers, Proteomics, Chemokine CXCL12, Alzheimer Disease. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCD NIH HHS, NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Plasma proteomic analyses of unique brain atrophy patterns may illuminate peripheral drivers of neurodegeneration and identify novel biomarkers for predicting clinically relevant outcomes. METHODS We identified proteomic signatures associated with machine learning‐derived aging‐ and Alzheimer's disease (AD) ‐related brain atrophy patterns in the Baltimore Longitudinal Study of Aging ( n = 815). Using data from five cohorts, we examined whether candidate proteins were associated with AD endophenotypes and long‐term dementia risk. RESULTS Plasma proteins associated with distinct patterns of age‐ and AD‐related atrophy were also associated with plasma/cerebrospinal fluid (CSF) AD biomarkers, cognition, AD risk, as well as mid‐life (20‐year) and late‐life (8‐year) dementia risk. EFEMP1 and CXCL12 showed the most consistent associations across cohorts and were mechanistically implicated as determinants of brain structure using genetic methods, including Mendelian randomization. DISCUSSION Our findings reveal plasma proteomic signatures of unique aging‐ and AD‐related brain atrophy patterns and implicate EFEMP1 and CXCL12 as important molecular drivers of neurodegeneration. Highlights Plasma proteomic signatures are associated with unique patterns of brain atrophy. Brain atrophy‐related proteins predict clinically relevant outcomes across cohorts. Genetic variation underlying plasma EFEMP1 and CXCL12 influences brain structure. EFEMP1 and CXCL12 may be important molecular drivers of neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersProteomicsChemokine CXCL12Alzheimer DiseaseBrainExtracellular Matrix ProteinsHumansFemaleMaleAgedLongitudinal StudiesAgingAtrophyAged, 80 and overMiddle AgedCohort Studies

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkersinflammationneurodegenerationproteomics

Substanzen

BiomarkersChemokine CXCL12EFEMP1 protein, humanExtracellular Matrix ProteinsCXCL12 protein, human

Autor:innen und Institutionen

  • Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.
  • Artificial Intelligence in Biomedical Imaging Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Laboratory of Artificial Intelligence and Biomedical Science, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Michael R Duggan

Förderung

  • NIDCD NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIH
  • NINDS NIH HHS
  • Intramural Research Program
  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Duggan, M. R., Yang, Z., Cui, Y., Dark, H. E., Wen, J., Erus, G., Hohman, T. J., Chen, J., Lewis, A., Moghekar, A., Coresh, J., Resnick, S. M., Davatzikos, C., & Walker, K. A. (2024). Proteomic analyses reveal plasma EFEMP1 and CXCL12 as biomarkers and determinants of neurodegeneration. Alzheimer's & Dementia, 20(9), 6486-6505. https://doi.org/10.1002/alz.14142

Vancouver

Duggan MR, Yang Z, Cui Y, Dark HE, Wen J, Erus G, et al. Proteomic analyses reveal plasma EFEMP1 and CXCL12 as biomarkers and determinants of neurodegeneration. Alzheimer's & Dementia. 2024;20(9):6486-6505. doi:10.1002/alz.14142

BibTeX
@article{Duggan2024,
  author = {Duggan, Michael R and Yang, Zhijian and Cui, Yuhan and Dark, Heather E and Wen, Junhao and Erus, Guray and Hohman, Timothy J and Chen, Jingsha and Lewis, Alexandria and Moghekar, Abhay and Coresh, Josef and Resnick, Susan M and Davatzikos, Christos and Walker, Keenan A},
  title = {Proteomic analyses reveal plasma EFEMP1 and CXCL12 as biomarkers and determinants of neurodegeneration},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {9},
  pages = {6486--6505},
  doi = {10.1002/alz.14142}
}
Kostenlos starten →